Does C33 require prior authorization?

No, C33 does not require prior authorization (high confidence). Code is covered without prior authorization.

Verity

`C33`, Malignant neoplasm of trachea

ICD-10-CM

Prior Authorization

No Prior Auth Required

Code is covered without prior authorization (high confidence)

Documentation Required

The intravitreal injection procedure must be coded using CPT code 67028 and the appropriate RT, LT, or 50 site modifier must be appended to indicate unilateral or bilateral service.
Dose and frequency for bevacizumab and biosimilars must follow the FDA label or recognized compendia for off-label uses; compendia cited include AHFS, Clinical Pharmacology, Lexi-Drugs, Micromedex DrugDex, NCCN, FDA, and USP.
When billing for metastatic (secondary) disease, use the code for the primary malignancy if the primary tumor is still present, and use the appropriate personal history 'Z' code if the primary malignancy is no longer present.
For Part A and Part B submissions, follow the respective HCPCS coding guidance provided (codes differ by drug form, biosimilar, and effective dates); bill units consistent with the indicated HCPCS code descriptions.

Key Coverage Criteria

For non-ophthalmologic (systemic) use, bevacizumab must be reported with HCPCS code J9035 (injection, bevacizumab, 10 mg) with units reflecting multiples of 10 mg provided.
For non-ophthalmologic use, bevacizumab-awwb (MVASI) must be reported with HCPCS code Q5107 (10 mg).
For non-ophthalmologic use, bevacizumab-bvzr (ZIRABEV) must be reported with HCPCS code Q5118 (10 mg).
Bevacizumab-maly (ALYMSYS/ALYMSYS1) is reported with HCPCS code C9142 for 10/01/2022–12/31/2022 and with HCPCS code Q5126 effective 01/01/2023 (10 mg).
Bevacizumab-adcd (Vegzelma) should be reported with HCPCS code Q5129 effective 04/01/2023.
For the period 09/27/2022 through 03/31/2023 bevacizumab-maly could be reported with miscellaneous code J3590 (per guidance for that timeframe).

20 Active Policies

CGS-L38065, MolDX: Plasma-Based Genomic Profiling in Solid Tumors

J15

CGS-L38067, MolDX: Next-Generation Sequencing for Solid Tumors

J15

CGS-L36021, MolDX: Molecular Diagnostic Tests (MDT)

J15

CGS-L34037, Flow Cytometry

J15

CGS-L36658

Have a follow-up question?

Ask Verity about documentation requirements, denial risks, or coverage in your state.

When reporting the JW modifier for discarded drug, the medical record must clearly show the amount administered and the amount wasted.

Medical record must document prior anthracycline therapy for patients receiving albumin-bound paclitaxel, or clearly document a clinical contraindication to anthracycline therapy.

, Proton Beam Therapy

CGS-L40225, MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer

J15

CGS-L37903, MolDX: Inivata, InVisionFirst®, Liquid Biopsy for Patients with Lung Cancer

J15

CGS-L38822, MolDX: Minimal Residual Disease Testing for Cancer

J15

CGS-L34356, Erythropoiesis Stimulating Agents (ESA)

J15

A57858, Billing and Coding: MolDX: Next-Generation Sequencing for Solid Tumors

A56333, Billing and Coding: MolDX: Inivata, InVisionFirst, Liquid Biopsy for Patients with Lung Cancer

A58468, Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers

A55147, Billing and Coding: MolDX: bioTheranostics Cancer TYPE ID Update

A57936, Billing and Coding: MolDX: Plasma-Based Genomic Profiling in Solid Tumors

A58756, Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer

A52370, Billing and Coding: Bevacizumab and biosimilars

A57452, Billing and Coding: Peripheral Nerve Blocks

A56867, Billing and Coding: Genomic Sequence Analysis Panels in the Treatment of Solid Organ Neoplasms

A56199, Billing and Coding: Molecular Pathology Procedures

A52450, Billing and Coding: Paclitaxel (e.g., Taxol/Abraxane )

C33, Malignant neoplasm of trachea